300 results about "Treatment use" patented technology

The present invention relates to a macrocyclic compound and a therapeutic use thereof. Disclosed in the present invention is a compound of formula (I), a pharmaceutically acceptable salt of said compound, a solvate of said compound, or a solvate of said pharmaceutically acceptable salt, and a use thereof in the preparation of a drug for treating cancer.

The present invention relates to a new method for assessing acceptability ranges or cut-offs for the compliance validation of batches of products comprising or consisting of one or more natural matrix, wherein said products have an ascertained therapeutic or beneficial effect. The invention also relates to a new process for the compliance validation of one or more batches of said products.

A method for authorizing a treatment may include receiving a treatment authorization request, creating an extracted text of a historical record using optical character recognition on the historical record, determining whether to analyze authorization performance of the treatment using a machine learning authorization process, in response to a determination to analyze authorization performance of the treatment using a machine learning authorization process: identifying authorization criteria for the treatment based on treatment authorization guidelines; identifying a natural language record processing model corresponding to expense authorization guidelines, and performing natural language processing on the extracted text of the record in accordance with the identified natural language record processing model to identify relevant record data in the record, determining whether the relevant record data meets the authorization criteria and in response to a determination that the relevant record data meets the authorization criteria, authorizing the performance of the treatment.

The present invention relates to macrocyclic compounds and therapeutic uses thereof. Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, solvates thereof or solvates of the pharmaceutically acceptable salts, and their use in the preparation of medicaments for the treatment of cancer.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

Compositions comprising a first polypeptide comprising a first fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain and a second polypeptide comprising a second fragment of an N-terminal extracellular domain of TSHR or an analog or derivative thereof and a dimerization domain are provided. Polypeptides comprising fragments of an N-terminal extracellular domain of TSHR comprising at least one mutation that increases solubility, decreases aggregation or both are also provided. Pharmaceutical compositions comprising the composition, polypeptide, nucleic acid systems and molecules encoding the polypeptides of the composition and invention and methods of treatment and determining suitability for treatment using the compositions or polypeptides; as well as methods of producing the compositions or proteins are also provided.

The present invention relates to a pharmaceutical combination product and a therapeutic use thereof. Specifically, the present invention provides a pharmaceutical combination product comprising a first pharmaceutically active ingredient and a second pharmaceutically active ingredient, wherein the first pharmaceutically active ingredient is a KRAS inhibitor. The present invention also provides a use for treating tumors, comprising administering the pharmaceutical combination product of the present invention to a subject in need.

The present invention relates to a compound of the formula (i) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a —COR4 group, (2) a —BOR5OR6 group, (3) a —X—Z group, (4) a (C1-C6)alkyl group or a (C1-C6)alkenyl group, (5) a —X—S(O)n(R7)p(R8)q group, (6) a halogen atom, a —NH2 group or a —CN group, (7) a —O—R11 group, (8) a —NH—COR9 group, (9) a —C(═NH)NHOH group, (10) a —NH—C(NH)—R9′ group, or (11) a —NHCOCOOR12 group or a —NHCOCONR12′R12″ group, X represents a bond, a —NH— group, a —CONH— group or a —CO— group, Z represents a 4 or 5-membered cycloalkyl, a 4 or 5-membered heterocylcloalkyl group, a 4 or 5-membered heteroaryl group or a phenyl group or a pharmaceutically acceptable salt thereof. The present invention further relates to a medicament comprising said compound of formula (I) and to said compound of formula (I) for use as an inhibitor and degrader of estrogen receptors.

This invention relates to the use of compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, in the treatment or prevention of mycobacterial infections, wherein: one of R2 and R3 is H, and the other is (CR) a R b ) n Y; Y is selected from CO2R c CN and CONR e R f R4 is selected from H, halogens, CN, alkyl and alkoxy groups; R6 is selected from H, F, Br, I, COOH, CN, COR. d CO2R d Alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, OH, SR d SOR d SO2R d SO2NR d R d NHSO2R d aryl and heteroaryl groups, wherein the aryl or heteroaryl group is optionally substituted by one or more substituents selected from alkyl, alkoxy, halogen, haloalkyl, and haloalkoxy groups; R7 is selected from H, halogen, alkyl, and alkoxy groups; R9 is selected from H, COR... d Alkyl, haloalkyl, aryl, CO-aryl, CO-haloaryl, aralkyl and haloaralkyl; R1, R5 and R8 are H; each R a R b R c R d R e and R f The compounds are independently selected from H, alkyl, and haloalkyl groups; n is 1 to 6. Other aspects of the invention relate to subgroups of compounds of formula (Ia), pharmaceutical compositions comprising such subgroups, and their use in the treatment or prevention of mycobacterial infections.

Methods of treating a condition which is treatable with SSR-125543 or a pharmaceutically acceptable salt thereof in a subject in need thereof are provided. The methods of treatment include predicting a treatment response of a subject to a treatment with SSR-125543 and / or detecting a polymorphism genotype associated with a treatment response of a subject to treatment with SSR-125543. Sets of at least one polymorphism genotype useful in the predicting and / or detecting steps are also disclosed.

Disclosed in the present invention are a pharmaceutical composition comprising a mixture of antibodies of anti-CTLA4 and anti-PD1, a pharmaceutical composition comprising the mixture of antibodies and a chemotherapeutic drug, and use of the above pharmaceutical composition in treating non-small cell lung cancer.

The present invention relates to formula (I): [Formula 1] A compound of TIFF2026514449000425.tif27170, or its tautomers, stereoisomers, salts, solvates, or N-oxides, wherein A 1 ~A 6 X, Y, R 7a , R 7b , R 8a , and R 8b The claims are as defined. The present invention further relates to pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, and their uses as agents, in particular as agents having METTL3 inhibitory activity, and advantageously for use in the treatment or prevention of cancer, or autoimmune diseases, neurological diseases, infectious diseases, or inflammatory diseases.

To provide a radionuclide complex solution of high concentration and high chemical stability which can be used as a medicine for diagnosis and / or treatment.SOLUTION: Provided is a pharmaceutical composition comprising: (a) a complex formed by: (ai) a radionuclide; and (aii) a gastrin releasing peptide receptor peptide antagonist binding moiety linked to a chelating agent; (b) at least two stabilizers against radiolysis; and (c) optionally a surfactant.SELECTED DRAWING: None

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.

Balloon based therapy devices for treatment of diseased vessels with particular applicability to veins are described. The devices are adapted for active aspiration of a closure zone, in particular aspects to an isolated closure zone, prior to delivery of a closure agent. The devices may be used for treatment of diseased veins in the lower limbs and pelvis. The devices may also include a plurality of angular offset abrasion elements adapted to engage with a vessel wall, such as along a treatment zone.

This application relates to, inter alia, anti-cMET antibody drug conjugates ("ADCs") having lower target-specific binding at low versus physiologic pH ("pH-ADCs"), pharmaceutical compositions including the pH-ADCs, methods of making the pH-ADCs, methods of selecting specific patient populations for cancer treatment with an anti-cMET pH-ADC, and methods of using the pH-ADCs to treat cancers, including cMET+ / cMET-expressing or cMET-overexpressing cancers, particularly including cMET+ / cMET-expressing or cMET-overexpressing non-small cell lung cancers ("NSCLCs").

A method for treating cartilage defects including providing a placental membrane preparation that comprises ground or minced placental membranes and optionally, a ground or minced cartilage and / or biocompatible glue, and introducing the preparation to a cartilage defect within a skeletal joint. The cartilage defect may comprise a hyaline cartilage defect, such as a chondral defect, or meniscal defect. The treatment may be provided in combination with other treatments such as marrow stimulation treatments and surgical repair treatments using sutures or other fixation techniques. The preparation promotes the regeneration of cartilage within the skeletal joint.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

Non-natural peptides having the ability to inhibit the A-kinase anchoring function of PI3K gamma, comprising an amino acid sequence as set forth in SEQ ID NO: 1, wherein each amino acid is a D-amino acid, and therapeutic uses and compositions thereof.

The disclosure relates to means and methods in the treatment of a subject having a colorectal cancer. The disclosure in particular relates to therapeutic uses and methods involving a bispecific antibody that binds EGFR and cMET. Such bispecific antibody is particularly useful in the treatment of metastatic colorectal cancer or a locally advanced, unresectable colorectal cancer. The disclosure further relates to uses in such methods and to the use in the manufacture of a medicament for the treatment of such cancers.

The present invention relates to compounds of Formula I, in which Y, Ar1, Ar2, X, R1, and R2 are defined herein, and to their use in various biological imaging techniques and therapeutic methods. The present invention relates, in aspects, to conjugates comprising compounds of Formula I and their related uses and therapeutic uses.

It relates to 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho [2, 3-d]imidazolium pamoate or solvate thereof, pharmaceutical composition comprising the pamoate salt or solvate, and therapeutic uses thereof. In particular, the pamoate salt or solvate is useful for treating cancer which has a c-My rearrangement and / or MYCN amplification or overexpression.

A treatment modality for use in the remediation of damaged tissues that involves protease down regulator solution impregnated microspheres, and the methods of production and therapeutic use thereof.

The field of the invention is in vitro assays for the production of in vitro organ culture systems and the use of such in vitro organ culture systems for screening assays in drug screening, patient selection and personalized medical context. More specifically, the present invention relates to an in vitro method of establishing a tumor organoid from a cancer tissue sample obtained from a subject, an in vitro method of providing immune cells activated by an autologous tumor organoid, a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject, and a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject. The invention relates to an in vitro organ culture system, and to an in vitro organ culture system produced thereby, to a method for determining the reactivity of a tumor to at least one immunooncology drug therapy using said in vitro organ culture system, and to a kit for preparing an in vitro organ culture system that mimics the interaction of a tumor with the immune system of a subject, as disclosed herein.

Disclosed herein are methods and devices for modifying appliance (100) material properties prior to or during orthodontic treatment. Orthodontic treatments with a modified appliance (100) are disclosed. The elasticity of the appliance material may be modified by the patient. The elasticity of the appliance (100) changes from an initial value (210) to a second value (220) greater than or less than the initial value (210). The modulus of the appliance material can be increased or decreased by changing the crosslinking amount of the polymer of the material, changing polymerization or crystallization, without changing the shape and / or color of the appliance (100). After a predetermined amount of expected tooth movement is achieved, the modulus of the appliance material is changed. The modification may be accomplished by one or more of exposure to specific light wavelengths and intensities, such as ultraviolet light or laser light, exposure to heat by which reactions within the appliance material are accomplished.

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

The electrical treatment device according to this design consists of a main unit and a cord connecting it to an electrical signal output unit, with the cord omitted in the diagram. The cord is connected to the black part that appears on the far right in the front view (the small circular black part that appears at the bottom of the right side view). In the front view, the five bullet-shaped tips extending upward from the top of the main unit are the connection terminals. When in use, the curved contact surfaces of the contact terminals are brought into contact with the area of ​​the person receiving treatment (for example, the face). Of the five connection terminals shown in the front view, the terminals located at both the left and right ends are not movable (non-movable connection terminals). In the front view, the three connection terminals located in the middle are each independently movable (movable connection terminals), and are constantly subjected to an upward biasing force from the main unit by a spring built into the main unit. When subjected to a force toward the main unit, they retract into the main unit against the biasing force of the spring. When subjected to a force directed toward the main body and fully immersed within it, the height of the tip contact surfaces of the three central contact terminals (possible connection terminals) is the same as the height of the tip contact surfaces of the contact terminals (non-movable connection terminals) at both ends of the main body (see reference diagram showing the state of use). On the other hand, when not subjected to a force directed toward the main body, the height of the tip contact surfaces of the three movable contact terminals is formed to be higher than the height of the tip contact surfaces of the contact terminals (non-movable connection terminals) at both ends of the main body, as shown in the front view, rear view, left side view, and right side view. When performing treatment using an electric treatment device according to this design, the electric treatment device is held by gripping it from the bottom side, and the curved tip contact surfaces of the contact terminals are brought into contact with the area of ​​the person receiving treatment. For example, when treating the face, the electric treatment device is held by gripping it from the bottom side, and the tip contact surfaces of the non-movable contact terminals are brought into contact with the face line area of ​​the person receiving treatment, so that the five contact terminals intersect with the face line area extending from below the chin towards the top of the head. From this position, with the tip of the central movable contact terminal still in contact with the face, the electrical treatment device is tilted so that the tip of the non-movable contact terminals on both the left and right sides of the main unit are in contact with the face, and then the treatment is performed. Next, with the tip of the central movable contact terminal still in contact with the face, the contact between the tip of the non-movable contact terminal on the main unit and the face is released, and the electrical treatment device is tilted so that the tip of the non-movable contact terminal on the upper side of the other side of the main unit is in contact with the face, and the treatment is performed.This procedure is performed by sequentially repeating the movements along the jawline, which extends from below the chin towards the top of the head. The same movements can be used to perform the treatment on other parts of the body of the person receiving the treatment using the electrical treatment device related to this design.

Disclosed herein are compounds of Formula I, and / or stereoisomers, stable isotopes, or pharmaceutically acceptable salts or solvates thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET) and potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.